LitCovid-sample-Enju  

PMC:7205724 / 18544-19470 JSONTXT 16 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T72940 0-5 CD denotes 4.2.2
T31699 7-16 NNP denotes Rationale
T6254 16-17 -COLON- denotes :
T80516 18-22 NN denotes IVIG
T69063 23-28 MD denotes might
T22631 29-33 VB denotes help
T88012 34-36 TO denotes to
T98862 37-44 VB denotes improve
T98671 45-48 DT denotes the
T20348 49-56 NN denotes outcome
T65200 57-59 IN denotes of
T90061 60-68 NNS denotes patients
T66297 69-73 IN denotes with
T53417 74-82 NN denotes COVID-19
T18993 83-86 DT denotes The
T21718 87-92 NN denotes study
T64168 93-94 -LRB- denotes [
T66430 94-96 CD denotes 23
T95152 96-97 -RRB- denotes ]
T31198 98-106 VBD denotes included
T55004 107-110 CD denotes ten
T65830 111-119 NNS denotes patients
T56952 120-124 IN denotes with
T98815 125-133 NN denotes COVID-19
T69048 134-137 WP denotes who
T75376 138-150 VBD denotes demonstrated
T59786 151-160 VBG denotes worsening
T24326 161-169 NNS denotes symptoms
T13700 169-170 -COMMA- denotes ,
T79561 171-175 FW denotes e.g.
T83448 175-176 -COMMA- denotes ,
T77014 177-186 VBD denotes decreased
T40148 187-197 NN denotes lymphocyte
T31095 198-203 NN denotes count
T13833 204-207 CC denotes and
T80531 208-217 VBD denotes decreased
T26060 218-227 NN denotes PaO2/FIO2
T3471 228-233 NN denotes ratio
T11859 234-237 CC denotes and
T6067 238-244 NN denotes oxygen
T65980 245-255 NN denotes saturation
T58632 255-256 -COMMA- denotes ,
T52543 257-266 VBG denotes following
T84435 267-276 NN denotes treatment
T44273 277-281 IN denotes with
T99668 282-283 DT denotes a
T65524 284-294 JJ denotes short-term
T66169 295-308 JJ denotes moderate-dose
T25963 309-323 NN denotes corticosteroid
T54040 324-325 -LRB- denotes (
T15835 325-343 NN denotes methylprednisolone
T75851 344-351 NN denotes 80 mg/d
T55858 351-352 -RRB- denotes )
T6426 353-357 CC denotes plus
T60445 358-372 NN denotes immunoglobulin
T91733 373-374 -LRB- denotes (
T10263 374-380 CD denotes 10 g/d
T89099 380-381 -RRB- denotes )
T32422 383-388 IN denotes After
T38661 389-398 VBG denotes switching
T47400 399-401 TO denotes to
T27854 402-405 DT denotes the
T88178 406-412 JJ denotes double
T22917 413-417 NN denotes dose
T27562 418-420 IN denotes of
T69861 421-430 NN denotes 1600 mg/d
T26688 431-449 NN denotes methylprednisolone
T91618 450-454 CC denotes plus
T63033 455-461 NN denotes 20 g/d
T82872 462-476 NN denotes immunoglobulin
T48110 476-477 -COMMA- denotes ,
T64285 478-481 DT denotes all
T67888 482-484 IN denotes of
T16788 485-488 DT denotes the
T67776 489-497 NNS denotes patients
T6163 498-506 VBN denotes improved
T27596 507-509 IN denotes in
T10929 510-513 DT denotes the
T87507 514-522 JJ denotes clinical
T10805 522-523 -COMMA- denotes ,
T49266 524-534 NN denotes laboratory
T95692 534-535 -COMMA- denotes ,
T51590 536-539 CC denotes and
T63732 540-552 JJ denotes paraclinical
T58895 553-561 NNS denotes outcomes
T85504 563-570 JJ denotes Passive
T86520 571-583 NN denotes immunization
T22143 584-592 VBZ denotes protects
T80547 593-600 IN denotes against
T21735 601-608 NN denotes disease
T15590 608-609 -COMMA- denotes ,
T4169 610-613 CC denotes and
T50400 614-616 IN denotes so
T4187 617-619 PRP denotes it
T38504 620-626 MD denotes should
T8453 627-629 VB denotes be
T27914 630-642 VBN denotes administered
T25991 643-645 RB denotes as
T54707 646-651 RB denotes early
T29802 652-654 IN denotes as
T24869 655-663 JJ denotes possible
T10896 664-668 WRB denotes when
T25638 669-672 DT denotes the
T29960 673-680 NN denotes patient
T20464 681-683 VBZ denotes is
T3036 684-693 VBN denotes diagnosed
T87261 695-702 NNS denotes Studies
T96660 703-707 VBP denotes show
T29990 708-712 IN denotes that
T81080 713-716 DT denotes the
T36950 717-722 JJ denotes viral
T53426 723-726 NN denotes RNA
T78293 727-729 IN denotes of
T18048 730-739 NN denotes 2019-nCoV
T93176 740-747 VBZ denotes reaches
T83675 748-751 PRP-DOLLAR- denotes its
T2594 752-756 NN denotes peak
T62926 757-763 IN denotes during
T35185 764-767 DT denotes the
T47524 768-773 JJ denotes first
T79772 774-778 NN denotes week
T85972 779-782 CC denotes and
T60597 783-787 RB denotes then
T18711 788-797 RB denotes gradually
T40522 798-807 VBZ denotes decreases
T67874 808-811 CC denotes and
T80013 812-816 IN denotes that
T48373 817-820 NN denotes IgG
T85015 821-824 CC denotes and
T48892 825-828 NN denotes IgM
T97802 829-834 VBP denotes begin
T54813 835-837 TO denotes to
T87582 838-842 VB denotes rise
T15243 843-847 IN denotes from
T79089 848-851 DT denotes the
T92830 852-856 JJ denotes 10th
T91091 857-860 NN denotes day
T75308 861-863 IN denotes so
T98992 864-868 IN denotes that
T91226 869-873 JJS denotes most
T66875 874-882 NNS denotes patients
T44373 883-887 VBP denotes have
T45012 888-898 JJ denotes anti-viral
T2304 899-909 NNS denotes antibodies
T90719 910-912 IN denotes by
T66178 913-916 DT denotes the
T38757 917-921 JJ denotes 14th
T73930 922-925 NN denotes day
R10340 T87582 T75308 arg1Of rise,so
R10355 T66875 T91226 arg1Of patients,most
R10991 T86520 T22143 arg1Of immunization,protects
R11936 T20348 T98671 arg1Of outcome,the
R13811 T2304 T44373 arg2Of antibodies,have
R14407 T21718 T64168 arg1Of study,[
R14592 T4187 T8453 arg1Of it,be
R14909 T58895 T10929 arg1Of outcomes,the
R15494 T87261 T96660 arg1Of Studies,show
R16551 T73930 T90719 arg2Of day,by
R16749 T10805 T51590 arg1Of ",",and
R16771 T13833 T13700 arg2Of and,","
R17219 T21718 T77014 arg1Of study,decreased
R17542 T6163 T48110 arg1Of improved,","
R1770 T77014 T13833 arg1Of decreased,and
R18986 T65980 T6067 arg1Of saturation,oxygen
R19341 T3471 T26060 arg1Of ratio,PaO2/FIO2
R19763 T20348 T65200 arg1Of outcome,of
R2046 T90061 T65200 arg2Of patients,of
R22057 T31095 T77014 arg2Of count,decreased
R22163 T24869 T29802 arg2Of possible,as
R22662 T84435 T44273 arg1Of treatment,with
R23868 T85972 T29990 arg1Of and,that
R25082 T22631 T6254 arg2Of help,:
R25333 T65830 T56952 arg1Of patients,with
R2548 T53426 T93176 arg1Of RNA,reaches
R2563 T82872 T63033 arg1Of immunoglobulin,20 g/d
R25803 T79772 T47524 arg1Of week,first
R2631 T97802 T80013 arg2Of begin,that
R26413 T6163 T32422 arg1Of improved,After
R26629 T13833 T79561 arg1Of and,e.g.
R27628 T87582 T97802 arg2Of rise,begin
R27976 T73930 T66178 arg1Of day,the
R28181 T27914 T8453 arg2Of administered,be
R28808 T44373 T75308 arg2Of have,so
R2970 T25963 T66169 arg1Of corticosteroid,moderate-dose
R29783 T29960 T25638 arg1Of patient,the
R31347 T98815 T75376 arg1Of COVID-19,demonstrated
R31644 T49266 T10805 arg2Of laboratory,","
R31769 T65830 T31198 arg2Of patients,included
R33163 T64285 T67888 arg1Of all,of
R33240 T80516 T98862 arg1Of IVIG,improve
R33852 T98862 T88012 arg1Of improve,to
R34129 T11859 T80531 arg2Of and,decreased
R35046 T64285 T38661 arg1Of all,switching
R35060 T73930 T38757 arg1Of day,14th
R35568 T67874 T96660 arg2Of and,show
R36109 T85972 T67874 arg1Of and,and
R36622 T91618 T27562 arg2Of plus,of
R36752 T84435 T6426 arg1Of treatment,plus
R37459 T80531 T13833 arg2Of decreased,and
R38202 T95152 T64168 arg3Of ],[
R39324 T13833 T58632 arg1Of and,","
R4003 T6426 T52543 arg2Of plus,following
R40258 T91091 T79089 arg1Of day,the
R40351 T24326 T59786 arg1Of symptoms,worsening
R40508 T65980 T11859 arg2Of saturation,and
R40741 T79772 T35185 arg1Of week,the
R4076 T13833 T83448 arg1Of and,","
R41260 T60445 T91733 arg1Of immunoglobulin,(
R41521 T64285 T6163 arg1Of all,improved
R41915 T58895 T63732 arg1Of outcomes,paraclinical
R42427 T85015 T87582 arg1Of and,rise
R42816 T93176 T85972 arg1Of reaches,and
R43001 T53426 T40522 arg1Of RNA,decreases
R43963 T58895 T87507 arg1Of outcomes,clinical
R45006 T80516 T69063 arg1Of IVIG,might
R45063 T27914 T10896 arg1Of administered,when
R45642 T22917 T47400 arg2Of dose,to
R46464 T54707 T29802 arg1Of early,as
R46612 T65830 T55004 arg1Of patients,ten
R46705 T87507 T10805 arg1Of clinical,","
R47040 T26688 T69861 arg1Of methylprednisolone,1600 mg/d
R47106 T67776 T67888 arg2Of patients,of
R47112 T87582 T15243 arg1Of rise,from
R47262 T21718 T80531 arg1Of study,decreased
R48496 T85015 T97802 arg1Of and,begin
R48610 T40522 T18711 arg1Of decreases,gradually
R49635 T13833 T52543 arg1Of and,following
R50003 T25963 T65524 arg1Of corticosteroid,short-term
R50369 T21718 T18993 arg1Of study,The
R50386 T89099 T91733 arg3Of ),(
R50799 T27914 T50400 arg1Of administered,so
R50945 T29960 T20464 arg1Of patient,is
R51148 T22631 T69063 arg2Of help,might
R52755 T48373 T85015 arg1Of IgG,and
R52803 T51590 T95692 arg1Of and,","
R53013 T53426 T36950 arg1Of RNA,viral
R53372 T66875 T44373 arg1Of patients,have
R53482 T2594 T83675 arg1Of peak,its
R53992 T58895 T49266 arg1Of outcomes,laboratory
R54860 T91091 T15243 arg2Of day,from
R55232 T86520 T85504 arg1Of immunization,Passive
R56085 T22917 T88178 arg1Of dose,double
R56679 T79772 T62926 arg2Of week,during
R57386 T93176 T62926 arg1Of reaches,during
R58171 T87582 T54813 arg1Of rise,to
R58848 T21735 T80547 arg2Of disease,against
R59825 T82872 T91618 arg2Of immunoglobulin,plus
R59919 T24326 T75376 arg2Of symptoms,demonstrated
R60239 T48892 T85015 arg2Of IgM,and
R62745 T38661 T32422 arg2Of switching,After
R63324 T63732 T51590 arg2Of paraclinical,and
R64025 T22917 T27562 arg1Of dose,of
R66734 T98815 T69048 arg1Of COVID-19,who
R67204 T53417 T66297 arg2Of COVID-19,with
R68805 T54707 T25991 arg1Of early,as
R68832 T67776 T16788 arg1Of patients,the
R69581 T22143 T80547 arg1Of protects,against
R70326 T90061 T66297 arg1Of patients,with
R70781 T2594 T93176 arg2Of peak,reaches
R70932 T80516 T22631 arg1Of IVIG,help
R70976 T25963 T99668 arg1Of corticosteroid,a
R71283 T44373 T90719 arg1Of have,by
R73123 T53426 T81080 arg1Of RNA,the
R75502 T10263 T91733 arg2Of 10 g/d,(
R7573 T53426 T78293 arg1Of RNA,of
R76274 T66430 T64168 arg2Of 23,[
R77199 T20348 T98862 arg2Of outcome,improve
R78212 T25963 T44273 arg2Of corticosteroid,with
R79029 T31095 T40148 arg1Of count,lymphocyte
R79224 T58895 T27596 arg2Of outcomes,in
R79540 T60445 T6426 arg2Of immunoglobulin,plus
R79576 T22917 T27854 arg1Of dose,the
R80044 T2304 T45012 arg1Of antibodies,anti-viral
R81041 T91091 T92830 arg1Of day,10th
R81045 T18048 T78293 arg2Of 2019-nCoV,of
R82140 T31699 T72940 arg1Of Rationale,4.2.2
R82498 T4187 T38504 arg1Of it,should
R82941 T75851 T54040 arg2Of 80 mg/d,(
R84704 T40522 T60597 arg1Of decreases,then
R86526 T21718 T31198 arg1Of study,included
R87834 T22143 T4169 arg1Of protects,and
R89140 T4169 T15590 arg1Of and,","
R89182 T25963 T54040 arg1Of corticosteroid,(
R89374 T75308 T98992 arg1Of so,that
R89732 T3036 T10896 arg2Of diagnosed,when
R90242 T98862 T22631 arg2Of improve,help
R91588 T27914 T4169 arg2Of administered,and
R92060 T6163 T27596 arg1Of improved,in
R92577 T3471 T11859 arg1Of ratio,and
R92905 T31198 T13700 arg1Of included,","
R9347 T3036 T20464 arg2Of diagnosed,is
R94232 T4187 T27914 arg2Of it,administered
R94705 T27914 T38504 arg2Of administered,should
R95496 T75851 T15835 arg1Of 80 mg/d,methylprednisolone
R96008 T29960 T3036 arg2Of patient,diagnosed
R9661 T98815 T56952 arg2Of COVID-19,with
R96845 T80013 T67874 arg2Of that,and
R96957 T26688 T91618 arg1Of methylprednisolone,plus
R97543 T38661 T47400 arg1Of switching,to
R98402 T27914 T54707 arg1Of administered,early
R99315 T40522 T85972 arg2Of decreases,and
R99597 T31699 T6254 arg1Of Rationale,:
R99800 T55858 T54040 arg3Of ),(